Vor Biopharma Inc. VOR
We take great care to ensure that the data presented and summarized in this overview for Vor Biopharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VOR
View all-
Paradigm Biocapital Advisors LP New York, NY6.46MShares$7.75 Million0.57% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA6.36MShares$7.63 Million5.32% of portfolio
-
Laurion Capital Management LP New York, NY3.18MShares$3.82 Million0.07% of portfolio
-
Black Rock Inc. New York, NY2.25MShares$2.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.81MShares$2.18 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA1.11MShares$1.33 Million0.03% of portfolio
-
Johnson & Johnson New Brunswick, NJ1.07MShares$1.29 Million0.54% of portfolio
-
Artal Group S.A. Luxembourg, N41MShares$1.2 Million0.13% of portfolio
-
Geode Capital Management, LLC Boston, MA841KShares$1.01 Million0.0% of portfolio
-
State Street Corp Boston, MA658KShares$789,2480.0% of portfolio
Latest Institutional Activity in VOR
Top Purchases
Top Sells
About VOR
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VOR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
14,645
-13.23%
|
$14,645
$1.39 P/Share
|
|
May 06
2024
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,361
-0.29%
|
$2,361
$1.75 P/Share
|
|
May 06
2024
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
875
-0.49%
|
$875
$1.75 P/Share
|
|
May 06
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
999
-0.89%
|
$999
$1.75 P/Share
|
|
May 06
2024
|
Nathan D. Jorgensen CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
834
-0.44%
|
$834
$1.75 P/Share
|
|
May 01
2024
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
985
-0.54%
|
$985
$1.77 P/Share
|
|
May 01
2024
|
Nathan D. Jorgensen CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
917
-0.48%
|
$917
$1.77 P/Share
|
|
May 01
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,146
-1.02%
|
$1,146
$1.77 P/Share
|
|
May 01
2024
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,751
-0.34%
|
$2,751
$1.77 P/Share
|
|
Mar 01
2024
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,657
-1.53%
|
$25,314
$2.27 P/Share
|
|
Mar 01
2024
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
5,576
-2.99%
|
$11,152
$2.27 P/Share
|
|
Mar 01
2024
|
Nathan D. Jorgensen CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
6,310
-3.2%
|
$12,620
$2.27 P/Share
|
|
Feb 06
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,180
-1.03%
|
$2,360
$2.32 P/Share
|
|
Feb 06
2024
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,033
-0.55%
|
$2,066
$2.32 P/Share
|
|
Feb 06
2024
|
Nathan D. Jorgensen CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
985
-0.5%
|
$1,970
$2.32 P/Share
|
|
Feb 06
2024
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,788
-0.34%
|
$5,576
$2.32 P/Share
|
|
Jan 29
2024
|
Robert Ang PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+15.29%
|
-
|
|
Jan 29
2024
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
53,750
+22.26%
|
-
|
|
Jan 29
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+35.4%
|
-
|
|
Jan 29
2024
|
Nathan D. Jorgensen CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+20.12%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 316K shares |
|---|
| Payment of exercise price or tax liability | 76.1K shares |
|---|---|
| Open market or private sale | 14.6K shares |